Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Instil Bio Inc. (NASDAQ:TIL) saw its stock jump 10% after the company announced that the U.S. Food and Drug Administration ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...